Welcome to our dedicated page for Lixte Biotechnology Hldgs SEC filings (Ticker: LIXT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lixte Biotechnology Holdings, Inc. filings document a clinical-stage oncology issuer developing cancer treatments through LB-100, Liora Technologies Europe and related platform assets. Annual and periodic disclosure categories cover operating and financial results, clinical and regulatory matters, capital structure, governance and the company's single reportable development segment.
Material-event filings record definitive agreements, subsidiary-level consulting and allocation arrangements, compensation changes, stock option cancellations, restricted share unit awards under the 2020 Stock Incentive Plan, and other capital-structure matters. Proxy materials cover shareholder voting, board governance and executive-compensation disclosures.
Nomad Power Solutions, Inc. reported a major upgrade to its Voyager mobile energy storage fleet, increasing standard usable capacity on the Voyager Eagle and Falcon to 2.025 MWh each and on the Voyager Hawk to 1.0 MWh. This delivers more than 50% additional energy per unit while keeping the trailer footprint, rated power output, and sub-one-hour deployment time unchanged, and will apply to all new Voyager units. The design uses prismatic lithium iron phosphate (LFP) packs from Octillion Power Systems to achieve higher energy density for data center and hyperscale customers who need more backup runtime without expanding site footprint.
Stazzone Peter reported acquisition or exercise transactions in this Form 4 filing.
LIXTE Biotechnology Holdings, Inc. reported that its Chief Financial Officer, Peter Stazzone, received an equity award of 50,000 shares of common stock on a grant or award basis, at a price of $0.00 per share. This award corresponds to 50,000 restricted share units (RSUs) that vest into one share of common stock each.
The footnotes state that these 50,000 RSUs vested after the achievement of performance conditions in the RSU agreement under the company’s 2020 Stock Incentive Plan. Following this award, Column 5 of the Form 4 reflects a total of 100,000 RSUs attributed to the reporting person, including the 50,000 newly awarded RSUs and 50,000 previously held RSUs, all of which have vested.
Sawyer Jason David reported acquisition or exercise transactions in this Form 4 filing.
LIXTE BIOTECHNOLOGY HOLDINGS, INC. director Jason David Sawyer received an equity award of 40,000 restricted stock units (RSUs). The grant was made under the company’s 2020 Stock Incentive Plan after performance conditions in his RSU agreement were satisfied. Following this award, he holds 65,000 RSUs, all of which have vested.
Lixte Biotechnology Holdings CEO Geordan Garrett Pursglove reported an acquisition of equity-based compensation through restricted share units. On July 1, 2026, he received 350,000 RSUs at a stated price of $0.00 per share as a grant or award.
Each RSU represents a right to receive one share of common stock upon vesting, tied to continued service and performance conditions that have already been satisfied. After this award, his reported holdings total 700,000 RSUs, including the 350,000 newly awarded RSUs and 350,000 RSUs that have fully vested.
Primus Guy Warren reported acquisition or exercise transactions in this Form 4 filing.
Lixte Biotechnology Holdings director Guy Warren Primus received 15,000 restricted stock units (RSUs) as an equity award. The RSUs were granted under the company’s 2020 Stock Incentive Plan at no cash cost and vest upon achievement of performance conditions, which have already been satisfied.
After this award, Primus reports a total of 40,000 RSUs, including 25,000 previously granted RSUs that have vested. This is a compensation-related grant rather than an open-market share purchase or sale.
Holloway Michael Andrew reported acquisition or exercise transactions in this Form 4 filing.
Lixte Biotechnology Holdings director Michael Andrew Holloway received an equity award of 15,000 restricted share units (RSUs). The RSUs were granted under the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan and an applicable RSU agreement.
Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 15,000 RSUs vested after the performance conditions in his RSU agreement were satisfied. Following this award, the total reported in his holdings is 40,000 RSUs, consisting of the 15,000 new RSUs and 25,000 previously granted RSUs, all of which have vested.
Felix Lourdes reported acquisition or exercise transactions in this Form 4 filing.
LIXTE Biotechnology Holdings director Felix Lourdes received a grant of 30,000 restricted share units (RSUs) under the company’s 2020 Stock Incentive Plan. The RSUs represent the right to receive an equal number of common shares upon vesting, and the performance conditions for these 30,000 RSUs have been satisfied.
After this award, Lourdes holds a total of 55,000 RSUs, including 25,000 RSUs that have already vested. The grant was a compensation award with no cash paid per share.
Lixte Biotechnology Holdings, Inc. has completed its merger with NOMAD Transportable Power Systems, making NOMAD a wholly owned subsidiary and shifting the business toward mobile, utility-grade battery energy storage systems.
As merger consideration, NOMAD stockholders received 2,992,041 shares of common stock and 50,366.07 shares of new Series D Non-Voting Convertible Preferred Stock, which are convertible into up to 50,366,070 common shares at a $1.00 conversion price after stockholder approval. The company is changing its name to Nomad Power Solutions, Inc. effective July 3, 2026, and its NASDAQ ticker from LIXT to NMAD effective July 6, 2026.
The Series D Preferred Stock carries a $1,000 liquidation value per share and will accrue a 7% annual cash dividend, payable quarterly, if required stockholder approval is not obtained within one year. Lixte’s board also appointed NOMAD CEO John Travaglini as a director and approved bylaw and charter changes to support the new capital structure and governance. Registration rights and stockholder support agreements were entered into, and the company will seek stockholder approval for conversion of the preferred stock, an increase in authorized shares, and director elections at a meeting expected around September 4, 2026.
LIXTE Biotechnology Holdings filed an initial insider ownership report for director John Francis Travaglini. This Form 3 identifies him as a director, not an officer or 10% owner. The data provided shows no reported transactions or existing derivative positions at this time.
LIXTE Biotechnology Holdings, Inc. entered into a secured financing tied to its planned acquisition of NOMAD Transportable Power Systems. The company issued a $6.5 million Secured Promissory Note to NOMAD, secured by a first-priority security interest in substantially all of NOMAD’s assets.
The note’s proceeds will repay NOMAD’s existing loan with BPCP Investment Holdings and support NOMAD’s working capital and general corporate purposes as it scales to meet an active order pipeline. The note matures in 30 days, with automatic 30‑day extensions while the merger agreement remains in effect, and its principal will be offset against merger consideration at closing.
If the merger is terminated due to a breach by LIXTE, the note becomes repayable within six months; if terminated due to a breach by NOMAD, it is due within three days. LIXTE expects the NOMAD acquisition to close on or about July 1, 2026, after which the combined company will be renamed NOMAD Power Solutions, Inc. and trade under a new ticker symbol on Nasdaq.